Understanding the regulation of a program of indcuible DNA replication driven by innate immune activation
Active Grant Awarded
- Award ID
- R56AI195966
- Recipient
-
The Regents Of The University Of Colorado UEI MW8JHK6ZYEX8 Part of The Regents Of The University Of Colorado
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $751,596
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 21% complete
- Place of performance
- Aurora, CO 80045, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $751,596 on September 9, 2026, under Allergy and Infectious Diseases Research (CFDA 93.855). The assistance type is a grant, identified as R56AI195966.
The award funds research testing whether NF-κB activation drives inducible DNA replication. The proposal examines how RelA recruits the MCM2 origin licensing factor to previously unused replication origins, producing transient extrachromosomal DNA from the interferon receptor (IFNR) locus on chromosome 21, and how these changes contribute to the NF-κB and interferon response to pathogens. Preliminary global analysis identified 179 candidate genomic regions, and transient amplification was confirmed at seven of these loci.
The full obligated amount is $751,596. The period of performance runs from September 9, 2026 to an ultimate completion date of August 31, 2027. Place of performance is Aurora, Colorado 80045. The source identifies no sub-recipients.
Description
- Abstract
- The inherent response to pathogens in all cells, innate immunity, is regulated by the activation and crosstalk of the NF-ΚB and interferon response factor signaling cascades. Decades of characterization has revealed a coordinated transcriptional response to foreign pathogens. However, IT has remained unclear if the activation of these innate immune response pathways drives additional nuclear changes that contribute to cellular responses to pathogens. We have uncovered that activation of NF-ΚB drives a program of inducible licensing of previously unused replication origins. This recruitment results in rapid changes in replication timing and the induction of targeted DNA rereplication. This targeted DNA rereplication creates extrachromosomal DNA (ECDNA), in the form of transient site-specific copy gain (TSSG) of the interferon receptor locus (IFNR) locus on chromosome 21. Analysis of IFNR TSSG events have demonstrated a reliance on the rela component of NF-ΚB which utilizes a specific DNA sequence element to recruit the MCM2 origin licensing factor and facilitate DNA rereplication and production of extrachromosomal DNA. Global analysis of inducible recruitment of MCM2 and rela identified 179 genomic regions that may also exhibit transient gene amplification in response to innate immune signaling. Confirmation of ECDNA produced from seven of these loci demonstrated a program of transient gene amplifications in response to innate immune signaling. Taken together, these data support the hypothesis that that NF-ΚB activation drives a program of inducible DNA replication origins that produce transient ECDNA of loci important for the heterogeneity in the innate immune response. This proposal seeks to answer several questions regarding how NF-ΚB drives a program of replication and rereplication and how these changes contribute to the NF-ΚB and interferon responses. 1) does nfκb drive genome wide changes in origin usage and replication timing? 2.) what are the regulators and enzymes required for nfκb driven tssgs? 3.) how does rela create a chromatin environment conducive to ECDNA production? And 4) how do tssgs of the IFNR locus contribute to the nfκb and interferon responses? We will use a combination of human cell culture models and primary mouse T cells to comprehensively determine the DNA replication program driven by NF-ΚB. We will establish the epigenetic and replication origin changes induced by NF-ΚB that promotes use of new replication origins. We will establish how NF-ΚB drives DNA rereplication of immune response genes and how this contributes to the heterogeneity of response to innate immune signaling. Finally, we will leverage our unique ability to both prevent and promote TSSG production to assess the importance of ECDNA in the innate immune response. Successful completion of the project will begin to establish how inducible ECDNA contributes to the cellular response to pathogens.
Quick answers
Who received award R56AI195966?
R56AI195966 was awarded to The Regents Of The University Of Colorado by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award R56AI195966 worth?
$751,596 has been obligated on R56AI195966.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award